Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Live Q&A: HCM Around the Globe: Not an Isolated Issue

Premiere Date: Thursday, June 30, 2022

This activity offers CE credit for:

1. Medicine (accme)
2. Nursing (ANCC)
3. Pharmacy (acpe)
4. PA (aapa)
5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Friday, June 30, 2023
Note: Credit Is No Longer Available

Faculty

Martin S. Maron, MD (Moderator) Director, Hypertrophic Cardiomyopathy Center Co-Director, Cardiac CT and MRI Assistant Professor Tufts University School of Medicine Boston, MA

Iacopo Olivotto, MD  Professor Head, Cardiomyopathy Unit Careggi University Hospital University of Florence Florence, Italy

Marco Antonio Rodrigues Torres, MD, PhD  Post Graduation Professor Federal University of Rio Grande do Sul (UFRGS) Porto Alegre, Brazil

Statement of Need

Hypertrophic cardiomyopathy (HCM) is the most common inherited monogenic cardiovascular disease, yet it is frequently overlooked as a cause of cardiac symptoms. Key diagnostic strategies include echocardiography and cardiovascular MRI. Evaluating patients with HCM for provocable left ventricular outflow obstruction (LVOT) can help to identify more patients with treatable obstructive disease. Once diagnosed, treatment options include β-adrenergic receptor blockers and calcium channel blockers. Disopyramide can be effective as an add-on therapy but is associated with side effects and contraindications. In experienced centers, septal myectomy or alcohol septal ablation can lead to near-complete resolution of resting and inducible LVOT gradients, but experienced surgeons and specialized centers are limited in many parts of the world. Most recently, a first-in-class oral myosin inhibitor, mavacamten, was approved by the FDA for obstructive HCM, providing a new, non-invasive option for appropriate patients.

In this live Q&A session, three international experts from the CME Outfitters “Snack” series on HCM come together to answer your questions about optimizing the management of HCM, including the role of myosin inhibition.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Screen appropriate patients for HCM using evidence-based diagnostic strategies.
• Implement global and country-specific practice guideline recommendations to improve care for patients with HCM.
• Assess study results of emerging HCM disease-specific treatments targeting cardiac myosin.

Financial Support

Supported by an educational grant from Bristol Myers Squibb.

Target Audience

Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons (Secondary: Primary care physicians/General practitioners, PAs, nurse practitioners, nurses, and pharmacists)

Credit Information

EACCME:
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Maron reports the following financial relationships:

Advisory Board: Cytokenetics (REDWOOD-HCM Steering Committee)

Consultant: Imbria and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Olivotto reports the following financial relationships:

Advisory Board: Amicus Therapeutics, Inc.; Bristol Myers Squibb; Cytokinetics; and Tenaya Therapeutics

Consultant: Amicus Therapeutics, Inc.; Bayer; Bristol Myers Squibb; Cytokinetics; Genzyme; and Tenaya Therapeutics

Dr. Torres reports no financial relationships.

The following CME Outfitters staff have no financial relationships:

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)

Warren Beckman (planning committee)

Evan Luberger (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).